Varian Medical Systems Receives FDA 510(k) Clearance for Eye Cancer Proton Therapy Treatment Planning Tool | Varian

Varian Medical Systems Receives FDA 510(k) Clearance for Eye Cancer Proton Therapy Treatment Planning Tool

PALO ALTO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Varian Medical Systems, Inc. (NYSE: VAR) has received FDA 510(k) clearance for a new proton therapy eye dose calculation module that has been made part of the company's Eclipse™ treatment planning system for planning radiation therapies for the treatment of cancer. The new proton eye dose calculation module, the first of its kind to be cleared by the FDA for use in the United States, enables doctors to create the highly complex treatment plans necessary for precisely delivering proton radiation beams for treatment of ocular cancers while maximizing protection for the many small, essential critical structures in and around the human eye.

Varian's Eclipse™ radiotherapy treatment planning system is the market leading clinical tool for planning advanced forms of radiation therapy, including photon (X-ray), electron, proton, and brachytherapy treatments. This comprehensive integrated approach enables clinicians to plan treatments using combinations of these modalities for the best possible care. Planners efficiently use the same tools for all of their work.

Proton radiotherapy is a highly precise form of cancer treatment that is only available in a few treatment centers worldwide. With the addition of the proton eye dose calculation, these treatment centers will now be able to treat cancers of the eye using this form of radiation therapy.

Varian Medical Systems, Inc., of Palo Alto, California is the world's leading manufacturer of integrated cancer therapy systems, which are treating thousands of patients per day. The company is also a premier supplier of X- ray tubes and flat-panel digital subsystems for imaging in medical, scientific, and industrial applications. Varian Medical Systems employs approximately 3,600 people who are located at manufacturing sites in North America and Europe and in its 56 sales and support offices around the world. Additional information is available on the company's web site at http://www.varian.com/.

Forward Looking Statements

Statements in this press release regarding future business, events, plans, objectives, expectations, estimates, and other similar matters constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the risks described in the company's Annual Report on Form 10-K and other reports filed from time to time by the Company with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this press release. The Company assumes no obligation to update or revise these forward-looking statements because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
   Spencer Sias (650) 424-5782
   spencer.sias@varian.com
   Meryl Ginsberg (650) 424-6444
   meryl.ginsberg@varian.com

SOURCE: Varian Medical Systems, Inc.

CONTACT: Spencer Sias, +1-650-424-5782 or spencer.sias@varian.com, or
Meryl Ginsberg, +1-650-424-6444 or meryl.ginsberg@varian.com, both of Varian
Medical Systems, Inc.

Web site: http://www.varian.com/